Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease
SourceArthritis Research & Therapy, 21, 1, (2019), pp. 54
Article / Letter to editor
Display more detailsDisplay less details
Arthritis Research & Therapy
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.